Özlem Türeci to Antibodies, Monoclonal
This is a "connection" page, showing publications Özlem Türeci has written about Antibodies, Monoclonal.
Connection Strength
0.230
-
A phase I dose-escalation study of IMAB362 (Zolbetuximab) in patients with advanced gastric and gastro-oesophageal junction cancer. Eur J Cancer. 2018 09; 100:17-26.
Score: 0.187
-
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature. 2017 07 13; 547(7662):222-226.
Score: 0.044